Filing Flows › Protalix BioTherapeutics (PLX) › Q4 2025
Protalix BioTherapeutics (PLX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 18, 2026
Protalix BioTherapeutics (PLX) reported revenue of $9.1M for the fourth quarter 2025 (Q4 2025), -50% from a year earlier and -49% from the quarter before. Operating margin was -51.1%, net loss $5.5M (60.3% of revenue).
Protalix BioTherapeutics, Q4 2025: revenue $9.1M (-50% year over year), operating margin -51.1%, net loss $5.5M, operating cash flow $2.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.1M | -49% | -50% |
| Operating profit | −$4.7M | -319% | -165% |
| Net earnings | −$5.5M | -334% | -185% |
| Operating cash flow | $2.0M | — | -49% |
| Free cash flow | $1.6M | — | -54% |
What changed
Revenue was $9.1M in Q4 2025, down 50% year over year and down 49% from the previous quarter. GOODS was the largest line at 95% of revenue.
Operating costs exceeded revenue by $4.7M, an operating margin of -51.1%. Total costs grew 25% against a revenue fall of 50%. The fastest-growing cost line was Research & development (+37%). The quarter ended with a net loss of $5.5M, after a profit of $2.4M the previous quarter.
Operating cash flow was $2.0M (down 49% year over year). Non-cash charges added back $387K of depreciation and $732K of share-based compensation. Working capital and other items added $6.4M. Capital expenditures of $403K left free cash flow of $1.6M.
Questions
What was Protalix BioTherapeutics' revenue in the fourth quarter 2025?
Protalix BioTherapeutics (PLX) reported revenue of $9.1M for the fourth quarter 2025 (Q4 2025), -50% from a year earlier and -49% from the quarter before.
Was Protalix BioTherapeutics profitable in the fourth quarter 2025?
Operating loss was $4.7M (-51.1% of revenue) and net loss $5.5M.